Highlights from Zacks analyst blog: NVIDIA, Philip Morris, Sanofi, Applied Materials and Goldman Sachs


For immediate release

Chicago, IL – December 15, 2021 – Zacks.com announces the list of stocks featured on the Analysts Blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Recent stocks featured in the blog include: NVIDIA Corporation NVDA, Philip Morris International Inc. PM, Sanofi SNY, Applied Materials, Inc. AMAT, and The Goldman Sachs Group, Inc. GS.

Here are highlights from Tuesday’s analyst blog:

Best stock market reports for NVIDIA, Philip Morris and Sanofi

Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including NVIDIA, Philip Morris and Sanofi. These research reports were handpicked from over 70 reports released today by our team of analysts.

You can see all today’s research reports here >>>

Actions of NVIDIA outperformed the Zacks General Semiconductor industry over the past year (+ 111% vs. + 58.5%). Zacks analyst believes NVIDIA has benefited from the wave of work and home learning due to the ongoing pandemic.

NVDA is also benefiting from strong growth in GeForce graphics processing units for desktops and notebooks, which is driving gaming revenue. An increase in demand Hyperscale remains a positive wind for its Data Center activity. The expansion of NVIDIA GeForce NOW is expected to boost the user base. NVIDIA management, however, expects the pandemic to impact short-term revenue.

(You can read the full research report on NVIDIA here >>>)

Philip morris stocks have gained + 15% during the year-to-date period against Zacks tobacco industry’s gain of + 12.3%. Zacks analyst believes that Philip Morris benefited from his pricing power, which also helped his third quarter 2021 results. PMs benefited from higher prices in most regions.

Another major strength for Philip Morris is strength in the Reduced Risk Product (or RRP) category. The popularity of IQOS has also been a powerful engine of growth for PM despite its supply challenges. The global semiconductor shortage, however, remains a major hurdle for Philip Morris. PM expects a limited recovery in its duty-free business in the fourth quarter as intercontinental travel remains subdued.

(You can read the full research report on Philip Morris here >>>)

Actions of Sanofi have lost -9.5% in the past six months against the Zacks Large Cap Pharmaceuticals industry gain of + 8.2%, although things appear to be improving. The Zacks analyst believes that Dupixent has become the main driver of Sanofi’s revenue due to the steady expansion of his label.

With accelerating revenues from outside the United States and multiple approvals for new indications expected in the near future, sales of Dupixent are expected to increase. Sanofi has a leading vaccines business, which contributes significantly to its sales. However, generic competition for several of its products remains a major obstacle for Sanofi.

(You can read the full research report on Sanofi here >>>)

Other noteworthy reports we present today include Applied Materials and Goldman Sachs.

Media contact

Zacks investment research

800-767-3771 ext 9339

[email protected]


Past performance is no guarantee of future results. The potential for loss is inherent in any investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a particular investor. It should not be assumed that any investment in any identified and described securities, companies, sectors or markets was or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or securities asset management activities. These returns come from hypothetical portfolios made up of stocks with a Zacks rank = 1 that have been rebalanced monthly without any transaction costs. These are not the returns of actual equity portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance numbers displayed in this press release.

5 actions in the process of doubling

Each has been handpicked by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations have climbed + 143.0%, + 175.9%, +498 , 3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Click to get this free report

The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report

Sanofi (SNY): Free Stock Analysis Report

Philip Morris International Inc. (PM): Free Stock Analysis Report

NVIDIA Corporation (NVDA): Free Inventory Analysis Report

Applied Materials, Inc. (AMAT): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.